Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

ASAQ (Malaria)


 
 
ASAQ to treat malaria

= Fixed dose combination of Artesunate + Amodiaquine
   
     



  • Launched in 2007

  • The concrete results of an innovative partnership between DNDi and Sanofi

  • Meets the latest WHO guidelines for malaria treatment in Africa

  • Simple regimen: 1 or 2 tablets once a day for 3 days

  • Available at only 0.5$ for children, 1$ for adults

  • Meets the highest standard of quality

  • Made in the South for use in the South: ASAQ is produced in Marocco

  • Available under the name Artesunate-Amodiaquine Winthrop (ASAQ) for public market and Coarsucam for private market


Download ASAQ Press pack, March 1st 2007 [PDF 890KB]
Download ASAQ Newsletter, November 2009 [PDF 980KB]
Read more about ASAQ project
  ASAQ News
Implementation progress
More than 300 million treatments distributed

ASAQ registered in 34 countries

Technology transfer to African industry partner ongoing
Recent Scientific Publications
Malaria Journal, March 2014
Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009
Malaria Journal, July 2013
Efficacy of ASAQ and AL fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial 
Malaria Journal, July 2013
Tolerability and safety of ASAQ and AL fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia
 
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License